İnflamatuar Miyopatiler
Özet
İnflamatuar miyopatiler, iskelet kaslarında kronik iltihaplanma ve ilerleyici kas güçsüzlüğü ile seyreden ciddi sistemik hastalıklardır. Çocukluk döneminde en sık juvenil dermatomiyozit şeklinde görülür ve deri bulguları, kas zayıflığı, yorgunluk gibi belirtilerle karakterizedir. Tanı, klinik muayene, kas enzim düzeyleri ve görüntüleme yöntemleriyle konulmakta, tedavi ise kortikosteroidler ve immünsüpresif ilaçlarla yürütülmektedir. Erken teşhis ve uygun tedavi protokolleri, hastalığın neden olduğu komplikasyonların önlenmesinde ve kas fonksiyonlarının korunmasında kritik öneme sahiptir.
Inflammatory myopathies are serious systemic conditions characterized by chronic inflammation of skeletal muscles and progressive muscle weakness. Juvenile dermatomyositis is the most common form in children, typically presenting with hallmark skin manifestations, muscle weakness, and fatigue. Diagnosis relies on clinical examination, assessment of muscle enzyme levels, and imaging, while management primarily involves corticosteroids and immunosuppressive therapies. Early diagnosis and appropriate treatment protocols are critical for preventing complications and preserving muscle function.
Referanslar
Plotz PH, Rider GL, Targoff IN, Raben N, O’Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995;122:715– 24.
Banker BQ, Victor M. Dermatomyositis (systemic angiopathy) of childhood. Medicine (Baltimore) 1966; 45:261.
Robinson AB, Hoeltzel MF, Wahezi DM, et al. Clinical characteristics of children with juvenile dermatomyositis: the childhood arthritis and rheumatology research alliance registry. Arthritis Care Res (Hoboken) 2014;66(3):404–10.
Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 1999; 11:475.
Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007; 157(4):637–644.
Fardet L, Dupuy A, Gain M, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009;88(2):91–7.
Shah M, Mamyrova G, Targoff IN, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013;92(1):25–41.
Miller FW, Cooper RG, Vencovsky J, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 2013; 65(12):3239–3247.
Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med 2016;280(1):24–38
Lee PY, Li Y, Richards HB, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007; 56(11):3759–3769.
Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2014; 73(1):256–262.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292(8):403–7.
Lundberg IE, Tjarnlund A, Bottai M, et al. European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76:1955–64.
Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 2017; 76(2):329–40.
Wedderburn LR, Varsani H, Li CK, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis:a tool for potential use in clinical trials. Arthritis Rheum. 2007; 57(7):1192-201.
Feldman BM, Rider GL, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371(9631): 2201-2212
Amato AA, Kissel JT. Inflammatory Myopathies. Part XVII Neuromuscular Disorders. In: Swaiman KF, Ashwal S, Ferriero DM, et al. Swaiman’s Pediatric Neurology Principles and Practice. 6th edition. Philadephia Elsevier 2017. p. e2595-2604.
Needham M, Mastaglia FL. Immunotherapies for Immune-Mediated Myopathies: A Current Perspective. Neurotherapeutics. 2016; 13(1):132-46.
Huber AM, Mamyrova G, Lachenbruch PA, et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2014; 66(5):732–740.
Chawla J. Stepwise approach to myopathy in systemic disease. Front Neurol. 2011; 2:49.
